CTLT Insider Trading Activity and SEC Form 4 Filings
CTLT insider trading summary
No open-market insider purchases or sales of Catalent, Inc. (CTLT) have been reported on SEC Form 4 in the past 12 months.
Latest CTLT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 11, 2024 | Michelle R Ryan | Director | Sell | $167K (2,800 @ $59.70) |
| Oct 18, 2024 | Joseph Anthony Ferraro | SVP, General Counsel, CCO | Sell | $19K (320 @ $59.97) |
| Sep 26, 2024 | David McErlane | Group President, Biologics | Sell | $120K (1,994 @ $59.97) |
| Aug 2, 2024 | Aristippos Gennadios | Group Pres. Pharma & Consumer | Sell | $70K (1,169 @ $59.55) |
| Aug 2, 2024 | Ricky Hopson | Pres. BioProduct Delivery, CoS | Sell | $39K (662 @ $59.56) |
| Aug 2, 2024 | Scott Gunther | SVP, Quality & Reg. Affairs | Sell | $40K (666 @ $59.55) |
| Aug 2, 2024 | Lisa Evoli | SVP, Chief HR Officer | Sell | $230K (3,859 @ $59.67) |
| Aug 2, 2024 | Joseph Anthony Ferraro | SVP, General Counsel, CCO | Sell | $36K (608 @ $59.58) |
| Jul 29, 2024 | Ricky Hopson | Pres. BioProduct Delivery, CoS | Sell | $12K (206 @ $58.67) |
| Jul 29, 2024 | Aristippos Gennadios | Group Pres. Pharma & Consumer | Sell | $20K (349 @ $58.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.